Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?

Basit Öğe Kaydı
dc.contributor.authorKılıç, Hatice
dc.contributor.authorArgüder, Emine
dc.contributor.authorCivak, Musa
dc.contributor.authorDemir, Emre
dc.date.accessioned2024-10-18T08:16:36Z
dc.date.available2024-10-18T08:16:36Z
dc.date.issued2024en_US
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractIntroduction: It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. Materials and Methods: The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. Results: In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p< 0.05). Conclusion: In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
dc.description.provenanceSubmitted by Zeynep Umut NARİN (umutarslan@hitit.edu.tr) on 2024-10-18T08:15:31Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Zeynep Umut NARİN (umutarslan@hitit.edu.tr) on 2024-10-18T08:16:36Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2024-10-18T08:16:36Z (GMT). No. of bitstreams: 0 Previous issue date: 2024en
dc.identifier.citationKılıç H, Argüder E, Civak M, Gemcioğlu E, Kaya Kalem A, Hasanoğlu İ, et al. Is using inhaled corticosteroid effective against OVID19 pneumonia severity and mortality? Tuberk Toraks 2024;72(3):219-228.
dc.identifier.doi10.5578/tt.202403934
dc.identifier.issn0494-1373
dc.identifier.pmid39275934
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://hdl.handle.net/11491/9070
dc.identifier.wosWOS:001325316200006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorDemir, Emre
dc.language.isoen
dc.publisherTURKISH ASSOC TUBERCULOSIS & THORAX
dc.relation.ispartofTUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19en_US
dc.subjectAsthmaen_US
dc.subjectCOPDen_US
dc.subjectInhaled corticosteroiden_US
dc.subjectMortaliten_US
dc.titleIs using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu